Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Seattle Genetics

Seattle Genetics
1998 FOUNDED
PUBLIC STATUS
1K-5K EMPLOYEES
SGEN STOCK SYMBOL
4 INVESTMENTS
$107.66 SHARE PRICE (As of Thursday Closing)
Description

Seattle Genetics is a biotech firm focused on developing antibody-drug conjugates. The company's lead product, Adcetris, has received approval for advanced front-line, relapsed/refractory and post-consolidation Hodgkin lymphoma, anaplastic large-cell lymphoma, and two other subtypes of cutaneous T-cell lymphoma. The company has several other oncology programs in pivotal trials. Seattle Genetics also licenses its antibody-drug conjugate technology to a number of leading biotechnology and pharmaceutical companies.

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 21823 - 30th Drive South East
  • Bothell, WA 98021
  • United States

+1 (425) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Seattle Genetics’s full profile, request a free trial.

Seattle Genetics Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$62.90 - $122.36 $18.5B $106.65 -$1.88 1.2M 171M

Seattle Genetics Financials Summary

In Thousands,
USD
TTM
30-Sep-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 14,215,653 8,610,790 7,243,062 6,877,938
Revenue 801,422 654,700 482,250 418,147
EBITDA (298,164) (220,314) (134,618) (122,077)
Net Income (304,285) (222,693) (125,530) (140,111)
Total Assets 2,097,537 1,503,329 877,949 838,396
Total Debt 77,973
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Seattle Genetics Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Seattle Genetics‘s full profile, request access.

Request full access to PitchBook

Seattle Genetics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Seattle Genetics‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Seattle Genetics Competitors (45)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Genmab Formerly VC-backed Copenhagen, Denmark 000 00.000 000000000 00.000
00000000 Formerly VC-backed Alameda, CA 000 00000 0&0
000000 Formerly VC-backed Monrovia, CA 000 00000 00000000 00000
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 000000 - 000 00000
000000000 Formerly VC-backed Waltham, MA 000 00000 00000000 00000
To view this company’s complete list of competitors, request access »

Seattle Genetics Investments & Acquisitions (4)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 00000000 09-Mar-2018 000000000000000000 00000 Biotechnology 0000 0000000 00.0
0000000-00000 0000 01-Oct-2017 000000000 00000 00 000.00 Buildings and Property 0000 0000000 00.0
00000 00000 000000 01-Aug-2017 000000000000000000 000.00 Laboratory Services (Healthcare) 000000 00000 00.0
UNUM Therapeutics 11-Jun-2015 Early Stage VC 0000 Biotechnology 0000 0000000 00.0
To view this company’s complete investment and acquisition history, request access »

Seattle Genetics Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
0000 000000000000 11-Jun-2015 00000 00000 00 0000 Completed
  • 13 buyers
To view this company’s complete exits history, request access »

Seattle Genetics Executive Team (12)

Name Title Board
Seat
Contact
Info
Clay Siegall Ph.D Chief Executive Officer & Chairman
Todd Simpson Chief Financial Officer & Chief Accounting Officer
Vaughn Himes Ph.D Chief Technology Officer
Matt Onsum Ph.D Executive
Jean Liu JD Executive Vice President & General Counsel

4 Former Executives

You’re viewing 5 of 12 executives. Get the full list »

Seattle Genetics Board Members (10)

Name Representing Role Since Contact
Info
Clay Siegall Ph.D Seattle Genetics Chief Executive Officer & Chairman 000 0000
Daniel Welch Self Board Member 000 0000
David Gryska Self Board Member 000 0000
Felix Baker Ph.D Baker Bros. Advisors Board Member 000 0000
John Orwin Self Board Member 000 0000

2 Former Board Members

You’re viewing 5 of 10 board members. Get the full list »